<div id="readability-page-1"><p>Thrivent Financial for Lutherans lessened its position in shares of  Chemed Corporation (NYSE:CHE - Free Report) by 4.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 90,213 shares of the company's stock after selling 4,516 shares during the period. Thrivent Financial for Lutherans owned 0.62% of Chemed worth $43,928,000 at the end of the most recent reporting period.</p><ul><li>3 Recession-Ready Stocks That Thrive When the Economy Sputters</li></ul><p>Other institutional investors and hedge funds also recently made changes to their positions in the company. Creekmur Asset Management LLC bought a new stake in  Chemed in the 2nd quarter valued at about $28,000.  SVB Wealth LLC purchased a new position in shares of  Chemed in the first quarter worth about $30,000.  WPG Advisers LLC bought a new stake in shares of  Chemed in the first quarter valued at approximately $32,000.  Parkside Financial Bank &amp; Trust raised its position in shares of  Chemed by 86.3% in the second quarter. Parkside Financial Bank &amp; Trust now owns 95 shares of the company's stock valued at $46,000 after purchasing an additional 44 shares during the period.  Finally, Geneos Wealth Management Inc. lifted its stake in shares of  Chemed by 330.4% during the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company's stock valued at $61,000 after buying an additional 76 shares in the last quarter. Institutional investors own  95.85% of the company's stock. </p><h2>Insider Buying and Selling at Chemed</h2><p>In other news, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction on Monday, November 24th. The shares were sold at an average price of $437.55, for a total transaction of $875,100.00. Following the completion of the sale, the chief executive officer directly owned 94,197 shares of the company's stock, valued at approximately $41,215,897.35. The trade was a 2.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own  3.29% of the company's stock. </p><h2>Chemed Stock Performance</h2><p>Shares of CHE stock opened at $430.15 on Tuesday. The company has a market capitalization of $6.09 billion, a PE ratio of 22.75, a price-to-earnings-growth ratio of 2.40 and a beta of 0.46. Chemed Corporation has a 52-week low of $408.42 and a 52-week high of $623.60. The business's fifty day moving average is $435.66 and its 200 day moving average is $462.14. </p><p>Chemed (NYSE:CHE - Get Free Report) last announced its earnings results on Tuesday, October 28th. The company reported $5.27 earnings per share for the quarter, missing analysts' consensus estimates of $5.39 by ($0.12). Chemed had a return on equity of 25.89% and a net margin of 11.02%.The business had revenue of $624.90 million during the quarter, compared to the consensus estimate of $626.04 million. During the same quarter in the prior year, the company earned $5.64 earnings per share. Chemed's revenue was up 3.1% compared to the same quarter last year. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS.  On average, sell-side analysts forecast that  Chemed Corporation will post 21.43 EPS for the current fiscal year. </p><h2>Chemed Announces Dividend</h2><p>The business also recently declared a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Monday, November 17th were issued a $0.60 dividend. The ex-dividend date of this dividend was Monday, November 17th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.6%. Chemed's dividend payout ratio  is presently 12.69%. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of research analysts recently weighed in on the stock. Royal Bank Of Canada reduced their price objective on shares of Chemed from $589.00 to $572.00 and set an &#34;outperform&#34; rating for the company in a research note on Monday, November 10th. Bank of America cut their price target on Chemed from $610.00 to $595.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, September 10th. Jefferies Financial Group upgraded Chemed from a &#34;hold&#34; rating to a &#34;buy&#34; rating and lifted their price target for the company from $490.00 to $550.00 in a research report on Tuesday, September 2nd. Zacks Research raised Chemed from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Thursday, October 30th. Finally, Weiss Ratings  restated a &#34;hold (c-)&#34; rating on shares of Chemed in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Chemed presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $574.25.</p><p><b>View Our Latest Report on CHE</b></p><h2>Chemed Profile</h2> (Free Report)<p>Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.</p><h2>See Also</h2><ul><li>Five stocks we like better than Chemed</li><li>What is MarketRank™? How to Use it</li><li>ServiceNow’s $7 Billion Gamble: Panic or Opportunity?</li><li>Growth Stocks: What They Are, What They Are Not</li><li>Dell and HP Are Raising Prices—And Investors Should Take Note</li><li>Diversification Can Smooth Returns And Mitigate Portfolio Risk</li><li>Why DLocal Is the Top Emerging Market Fintech Stock to Watch for 2026</li></ul><p><strong>Want to see what other hedge funds are holding CHE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNIRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNIRQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Chemed Right Now?</h2><p>Before you consider Chemed, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.</p><p>While Chemed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Thrivent Financial for Lutherans decreased its stake in Chemed Corporation by 4.8% in Q2, now holding 90,213 shares worth $43.93 million. Other institutional investors also adjusted their positions. Chemed's CEO sold 2,000 shares. The company's Q3 earnings missed estimates, with revenue up 3.1% YoY. Chemed announced a $0.60 quarterly dividend. Analysts have mixed ratings, with some downgrades and upgrades.</p>

Thrivent Financial for Lutherans Decreases Stock Position in Chemed Corporation $CHE